JP2022524692A5 - - Google Patents

Info

Publication number
JP2022524692A5
JP2022524692A5 JP2021539095A JP2021539095A JP2022524692A5 JP 2022524692 A5 JP2022524692 A5 JP 2022524692A5 JP 2021539095 A JP2021539095 A JP 2021539095A JP 2021539095 A JP2021539095 A JP 2021539095A JP 2022524692 A5 JP2022524692 A5 JP 2022524692A5
Authority
JP
Japan
Prior art keywords
cancer
item
domain
tcrβv
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021539095A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022524692A (ja
JP7700039B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/012162 external-priority patent/WO2020142672A2/en
Publication of JP2022524692A publication Critical patent/JP2022524692A/ja
Publication of JP2022524692A5 publication Critical patent/JP2022524692A5/ja
Application granted granted Critical
Publication of JP7700039B2 publication Critical patent/JP7700039B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021539095A 2019-01-04 2020-01-03 抗tcr抗体分子およびその使用 Active JP7700039B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962788497P 2019-01-04 2019-01-04
US62/788,497 2019-01-04
US201962803893P 2019-02-11 2019-02-11
US62/803,893 2019-02-11
PCT/US2020/012162 WO2020142672A2 (en) 2019-01-04 2020-01-03 Anti-tcr antibody molecules and uses thereof

Publications (3)

Publication Number Publication Date
JP2022524692A JP2022524692A (ja) 2022-05-10
JP2022524692A5 true JP2022524692A5 (https=) 2023-03-06
JP7700039B2 JP7700039B2 (ja) 2025-06-30

Family

ID=71407087

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021539095A Active JP7700039B2 (ja) 2019-01-04 2020-01-03 抗tcr抗体分子およびその使用

Country Status (8)

Country Link
US (1) US20220064255A1 (https=)
EP (1) EP3906057A4 (https=)
JP (1) JP7700039B2 (https=)
CN (1) CN113543807A (https=)
AU (2) AU2020204686A1 (https=)
CA (1) CA3125345A1 (https=)
GB (1) GB2595980B (https=)
WO (1) WO2020142672A2 (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3548055A4 (en) 2016-12-02 2020-08-19 University of Southern California SYNTHETIC IMMUNE RECEPTORS AND THEIR PROCESSES FOR USE
US12247060B2 (en) 2018-01-09 2025-03-11 Marengo Therapeutics, Inc. Calreticulin binding constructs and engineered T cells for the treatment of diseases
EP3765517A1 (en) 2018-03-14 2021-01-20 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
CA3105448A1 (en) 2018-07-03 2020-01-09 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
CN119039441A (zh) 2019-02-21 2024-11-29 马伦戈治疗公司 与nkp30结合的抗体分子及其用途
GB2599228B (en) 2019-02-21 2024-02-07 Marengo Therapeutics Inc Multifunctional molecules that bind to T cell related cancer cells and uses thereof
MX2021010857A (es) 2019-03-11 2021-12-15 Janssen Biotech Inc Anticuerpos biespecificos anti-v(beta17)/anti-cd123.
WO2021097325A1 (en) * 2019-11-14 2021-05-20 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
AU2020416273A1 (en) * 2020-01-03 2022-07-28 Marengo Therapeutics, Inc. Anti-TCR antibody molecules and uses thereof
MX2023000984A (es) * 2020-07-23 2023-05-03 Dyne Therapeutics Inc Complejos dirigidos al musculo y usos de los mismos para el tratamiento de distrofinopatias.
EP4185320A4 (en) * 2020-07-23 2025-10-08 Dyne Therapeutics Inc MUSCLE TARGETING COMPLEXES AND THEIR USES IN THE TREATMENT OF MUSCLE ATROPHY
CN116194470B (zh) * 2020-07-23 2025-10-03 达因疗法公司 肌肉靶向复合物及其用途
CA3190987A1 (en) * 2020-08-10 2022-02-17 Janssen Biotech, Inc. Materials and methods for producing bioengineered virus specific lymphocytes
TW202227495A (zh) * 2020-09-11 2022-07-16 美商健生生物科技公司 用於調節β鏈介導之免疫的方法及組成物
US20220089737A1 (en) * 2020-09-11 2022-03-24 Janssen Biotech, Inc. Multi-specific immune targeting molecules and uses thereof
WO2022056197A1 (en) 2020-09-11 2022-03-17 Janssen Biotech, Inc. Immune targeting molecules and uses thereof
IL308258A (en) 2021-05-05 2024-01-01 Immatics Biotechnologies Gmbh Bma031 antigen binding polypeptides
CN115820697B (zh) * 2022-09-23 2024-07-30 中国海洋大学 一种免疫细胞及其制备方法和应用
JP2026501572A (ja) * 2022-12-27 2026-01-16 イェール ユニバーシティー Tcr-vbeta特異的治療用分子、及びその使用
CN120435501A (zh) * 2022-12-30 2025-08-05 上药生物治疗(香港)有限公司 细胞原位分泌抗体及其用途
WO2024197082A2 (en) * 2023-03-21 2024-09-26 Marengo Therapeutics, Inc. Tcr targeting molecules and uses thereof
AU2024240821A1 (en) 2023-03-23 2025-11-06 Bodhi Bio Llc Compositions and methods for antigen-specific therapy
EP4704897A1 (en) * 2023-04-27 2026-03-11 Marengo Therapeutics, Inc. Combination therapies using molecules binding to tcr
US20250074966A1 (en) * 2023-08-31 2025-03-06 Adaptive Biotechnologies Corporation Agents and methods for preventing or inhibiting adaptive immune responses associated with multiple sclerosis
WO2025051339A1 (en) * 2023-09-05 2025-03-13 Tiber Biotech Srl SINGLE-CHAIN VARIABLE FRAGMENT AND MOLECULES DERIVING THEREFROM THAT BIND FRAGMENT TRVB5-1 OF THE β CHAIN OF HUMAN T-CELL RECEPTOR
WO2026011097A1 (en) * 2024-07-03 2026-01-08 Yale University Antibody drug conjugates comprising tcr-vbeta specific therapeutic molecules and uses thereof
CN120064640B (zh) * 2025-01-15 2026-01-23 中牧实业股份有限公司 一种猪细小病毒vp2双抗体夹心定量检测试剂盒及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766947A (en) * 1988-12-14 1998-06-16 Astra Ab Monoclonal antibodies reactive with an epitope of a Vβ3.1 variable region of a T cell receptor
JPH0787994A (ja) * 1993-04-30 1995-04-04 Sumitomo Electric Ind Ltd T細胞抗原受容体Vβ22に対するモノクローナル抗体及びその製造方法
PL328790A1 (en) * 1996-10-04 1999-02-15 Univ Jefferson T-lymphocytes provoking an immunological response and methods of using them
AU2006300951A1 (en) * 2005-10-11 2007-04-19 Domantis Limited Antibody polypeptide library screening and selected antibody polypeptides
US20130273089A1 (en) * 2011-11-03 2013-10-17 Tolera Therapeutics, Inc. Antibody and methods for selective inhibition of t-cell responses
US20170335281A1 (en) * 2014-03-15 2017-11-23 Novartis Ag Treatment of cancer using chimeric antigen receptor
EA035419B9 (ru) * 2014-05-29 2020-08-07 Мэкроудженикс, Инк. Триспецифичные связывающие молекулы и способы их применения
LT3611192T (lt) * 2015-05-13 2025-06-25 Ablynx N.V. T ląstelių rekrutingo polipeptidai tcr alfa/beta reaktyvumo pagrindu
JP2018517712A (ja) * 2015-06-01 2018-07-05 メディジーン イミュノテラピーズ ゲーエムベーハー T細胞受容体特異的抗体
WO2017040930A2 (en) * 2015-09-03 2017-03-09 The Trustees Of The University Of Pennsylvania Biomarkers predictive of cytokine release syndrome
JP7291396B2 (ja) * 2016-11-22 2023-06-15 ティーシーアール2 セラピューティクス インク. 融合タンパク質を用いたtcrの再プログラミングのための組成物及び方法
CA3105448A1 (en) * 2018-07-03 2020-01-09 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof

Similar Documents

Publication Publication Date Title
JP2022524692A5 (https=)
US20220265721A1 (en) Treatment using chimeric receptor t cells incorporating optimized polyfunctional t cells
US10918667B2 (en) Modified cell expressing therapeutic agent and uses thereof
TWI862870B (zh) 嵌合抗原受體療法t細胞擴增動力學及其用途
JP2020532954A5 (https=)
JP7524465B2 (ja) 免疫細胞機能の改善
JP7690597B2 (ja) 免疫細胞機能の改善
TW202245812A (zh) 嵌合抗原受體t細胞療法
KR20260013488A (ko) 면역 이펙터 세포 및 이의 용도
TW202604968A (zh) 多肽系統
HK40011995A (en) Treatment using chimeric receptor t cells incorporating optimized polyfunctional t cells